Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 101–200 of 999
Tanaka, H., Homma, H., Fujita, K., Kondo, K., Yamada, S., Jin, X., Waragai, M., Ohtomo, G., Iwata, A., Tagawa, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14353-6 · Cited by 119
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance
Vico Varela, E., Etter, G., & Williams, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.010 · Cited by 118
Siedlecki-Wullich, D., Català-Solsona, J., Fábregas, C., Hernández, I., Clarimon, J., Lleó, A., Boada, M., Saura, C. A., Rodríguez-Álvarez, J., & Miñano-Molina, A. J. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0501-4 · Cited by 118
Self-citationLopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
“The aims of the API include conducting potentially label-enabling trials in cognitively unimpaired persons at high risk for the development of AD using novel composite clinical endpoints, thereby providing better tests of the amyloid hypothesis than trials that recently failed in clinical stages of the disease [19,24].”
BackgroundResultShabbir, U., Rubab, M., Tyagi, A., & Oh, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010196 · Cited by 127
“Thus, therapeutic agents that can target tau pathology, not only repair abnormality in tau but also restrain a series of reactions caused by the abnormality of tau could play a vital role in the treatment of AD [55].”
BackgroundThe need to show minimum clinically important differences in Alzheimer's disease trials
Liu, K. Y., Schneider, L. S., & Howard, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00197-8 · Cited by 113
Staging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Honig, L. S., Barakos, J., Dhadda, S., Kanekiyo, M., Reyderman, L., Irizarry, M., Kramer, L. D., Swanson, C. J., & Sabbagh, M. (2023) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12377 · Cited by 112
Self-citationOligomeric Aβ in the monkey brain impacts synaptic integrity and induces accelerated cortical aging
Beckman, D., Ott, S., Donis-Cox, K., Janssen, W. G., Bliss-Moreau, E., Rudebeck, P. H., Baxter, M. G., & Morrison, J. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902301116 · Cited by 111
“More recently, solanezumab, an antibody against Aβ, did not slow cognitive decline in patients who had some evidence of amyloid disease detected with an amyloid PET scan (71).”
BackgroundAyalon, G., Lee, S.-H., Adolfsson, O., Foo-Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H., Bravo, J., Brendza, R., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 110
Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer’s Disease
Dong, X., Nao, J., Shi, J., & Zheng, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00332 · Cited by 124
Gibson, G. E., Luchsinger, J. A., Cirio, R. T., Chen, H., Franchino‐Elder, J., Hirsch, J. A., Bettendorff, L., Chen, Z., Flowers, S. A., Gerber, L. M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200896 · Cited by 117
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
“Although preclinic and clinical studies show that Ab pathology is the major characteristic of AD, many clinical trials focusing on clearing Ab and decreasing Ab production have failed (8, 162, 209, 234, 405), indicating that track-Abonly is insufficient for AD treatment and that additional mechanisms are essential for…”
BackgroundPresent Algorithms and Future Treatments for Alzheimer’s Disease
Grossberg, G. T., Tong, G., Burke, A. D., & Tariot, P. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180903 · Cited by 128
Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy
Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020) · International Journal of Alzheimer's Disease · doi:10.1155/2020/5380346 · Cited by 107
“Results of phase III studies of solanezumab, an antibody targeting soluble Aβ peptides, were not able to show a significant decrease in cognitive decline when assessed by MMSE and ADAS-cog in treatment groups compared to the placebo [74].”
BackgroundMethodLiu, W., Lin, H., He, X., Chen, L., Dai, Y., Jia, W., Xue, X., Tao, J., & Chen, L. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0801-2 · Cited by 106
Immunotherapies for Neurodegenerative Diseases
Mortada, I., Farah, R., Nabha, S. M., Ojcius, D. M., Fares, Y., Almawi, W. Y., & Sadier, N. S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.654739 · Cited by 123
“However, due to its failure in reducing Aβ burden and in light of recent shortcomings in phase III trials that revealed that solaneuzumab did not improve cognitive decline in patients with mild AD, current trials were terminated due to less and less promising results (127, 128).”
BackgroundMinimal clinically important difference in Alzheimer's disease: Rapid review
Muir, R. T., Hill, M. D., Black, S. E., & Smith, E. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13770 · Cited by 124
Jayaraj, R. L., Azimullah, S., & Beiram, R. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2019.12.028 · Cited by 107
Hoogmartens, J., Cacace, R., & Van Broeckhoven, C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12155 · Cited by 104
Li, X., Wang, X., Su, L., Hu, X., & Han, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028188 · Cited by 106
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundMethodInfluentialBeyond the average patient: how neuroimaging models can address heterogeneity in dementia
Verdi, S., Marquand, A. F., Schott, J. M., & Cole, J. H. (2021) · Brain · doi:10.1093/brain/awab165 · Cited by 106
“patients (defined using PET) were recruited, reducing the ability to detect the effects with high levels of sensitivity, as some patients were likely following different pathological trajectories.(34,35) Subsequently, it has been argued that a stringent approach of”
BackgroundNew therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
“Amyloid-β (Aβ)-targeted immunotherapies and β-secretase (BACE1) inhibitors such as AN-1792 [3], bapineuzumab [4], solanezumab [5], aducanumab [6], gantenerumab [7], verubecestat [8], atabecestat [9], lanabecestat [10], and elenbecestat (E2609) [11] have shown a lack of efficacy in improving cognition in AD patients.”
BackgroundMullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Alawode, D. O. T., Heslegrave, A. J., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O´Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 104
Effects of neural stem cell transplantation in Alzheimer’s disease models
Hayashi, Y., Lin, H.-T., Lee, C.-C., & Tsai, K. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-0622-x · Cited by 118
“trials for Solanezumab, which is also targets Aβ aggregation [78].”
BackgroundAnti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
“Phase III, randomised, double-blind, placebo-controlled (EXPEDITION 3) 76 weeks [56] Mild AD ADAS-Cog11 No significant effects Significant increase in plasma and CSF No significant effects No significant effects”
BackgroundPET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
“Although there have been no successful anti-Aβ drugs up to date, Aβ PET imaging has provided useful outcome measures for anti-Aβ therapeutics in clinical trials (Salloway et al., 2014; Honig et al., 2018; Wessels et al., 2020).”
BackgroundPathological Changes of Tau Related to Alzheimer’s Disease
Chu, D., & Liu, F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00457 · Cited by 102
Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
Kleffman, K., Levinson, G., Rose, I. V. L., Blumenberg, L. M., Shadaloey, S. A. A., Dhabaria, A., Wong, E., Galán-Echevarría, F., Karz, A., Argibay, D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1006 · Cited by 93
Self-citationCan we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Plog, B. A., Mestre, H., Olveda, G. E., Sweeney, A. M., Kenney, H. M., Cove, A., Dholakia, K. Y., Tithof, J., Nevins, T. D., Lundgaard, I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120922 · Cited by 101
“Despite promising preclinical results with this approach, results of clinical trials have been unimpressive and plagued by adverse events (8–10).”
Treating Alzheimer's disease by targeting iron
Nikseresht, S., Bush, A. I., & Ayton, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14567 · Cited by 98
“This prompted a further Phase 3 trial of mild AD cases, where the drug had no impact on disease progression (Honig et al., 2018).”
BackgroundAdvances in Alzheimer’s disease’s pharmacological treatment
Filho, C. E. C., Loss, L. B., Pereira, C. M., Rossoni, J. V., Barcelos, R. M., Chiarelli-Neto, O., da Silva, B. S., Ambrósio, R. P., Castro, F. C. D. A. Q., Teixeira, S. F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1101452 · Cited by 123
“Solanezumab (Honig et al., 2018; Liu-Seifert, et al., 2018), bapineuzumab (Arai et al.”
Ebell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 111
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology
Zou, P., Wu, C., Liu, T. C.-Y., Duan, R., & Yang, L. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00385-7 · Cited by 97
“…to date, nearly all of the interventions targeting Aβ and tau protein hyper-phosphorylation in AD have failed in phase III clinical trials [193–195], including immunotherapies, drugs reducing Aβ production or enhancing Aβ clearance, as well as drugs inhibiting tau phosphorylation or…”
BackgroundKuzu, O. F., Granerud, L. J. T., & Saatcioglu, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02439-w · Cited by 142
Randomized controlled trial of TDCS on cognition in 201 seniors with mild neurocognitive disorder
Lu, H., Chan, S. S. M., Chan, W. C., Lin, C., Cheng, C. P. W., & Linda Chiu Wa, L. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50823 · Cited by 96
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Sun, Y., Wang, Y., Chen, S.-T., Chen, Y.-J., Shen, J., Yao, W.-B., Gao, X.-D., & Chen, S. (2020) · Theranostics · doi:10.7150/thno.44370 · Cited by 93
“Unfortunately, in recent years, most mono-target drug candidates designed directly for Aβ or tau have not achieved desirable efficiency in clinical trials [7, 8].”
BackgroundPing, F., Jiang, N., & Li, Y. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001370 · Cited by 100
New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
Park, S. A., Han, S. M., & Kim, C. E. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0418-9 · Cited by 91
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 93
Gao, C., Chu, X., Gong, W., Zheng, J., Xie, X., Wang, Y., Yang, M., Li, Z., Gao, C., & Yang, Y. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00626-1 · Cited by 93
RetractedThe landscape of metabolic brain alterations in Alzheimer's disease
Batra, R., Arnold, M., Wörheide, M. A., Allen, M., Wang, X., Blach, C., Levey, A. I., Seyfried, N. T., Ertekin‐Taner, N., Bennett, D. A., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12714 · Cited by 93
BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92
Ono, K., & Tsuji, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030952 · Cited by 92
“In contrast, other clinical trials of monoclonal antibodies targeting fibrillar Aβ, such as bapineuzumab [63], or soluble monomeric Aβ, such as solanezumab [20], have failed to produce clinical effects.”
BackgroundResultTargeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies
Mallick, R., Basak, S., Chowdhury, P., Bhowmik, P., Das, R. K., Banerjee, A., Paul, S., Pathak, S., & Duttaroy, A. K. (2025) · Pharmaceuticals · doi:10.3390/ph18010104 · Cited by 119
“Solanezumab, an anti-amyloid monoclonal antibody that does not directly target cytokines, has shown promise in decreasing levels of neuroinflammatory indicators in CSF [173,174].”
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
BackgroundSelf-citationThe informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Wang, P., Yin, X., Chen, G., Li, L., Le, Y., Xie, Z., Ouyang, W., & Tong, J. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.05.001 · Cited by 94
Gofrit, O. N., Klein, B., Cohen, I. R., Ben‐Hur, T., Greenblatt, C. L., & Bercovier, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224433 · Cited by 95
Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
Weigand, A. J., Bangen, K. J., Thomas, K. R., Delano-Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, A. D. N. (2020) · Brain Communications · doi:10.1093/braincomms/fcz046 · Cited by 86
“Furthermore, the recent failures of large-scale clinical trials targeting Ab have called into question the verity of the amyloid cascade model (Egan et al., 2018; Honig et al., 2018; Selkoe, 2019).”
BackgroundVillain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 94
ENGAGE and EMERGE: Truth and consequences?
Kuller, L. H., & Lopez, O. L. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12286 · Cited by 83
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 85
Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
Zou, K., Abdullah, M., & Michikawa, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030085 · Cited by 83
A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
Gibbs, E., Silverman, J. M., Zhao, B., Peng, X., Wang, J., Wellington, C. L., Mackenzie, I. R., Plotkin, S. S., Kaplan, J. M., & Cashman, N. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-46306-5 · Cited by 82
Wang, L., & Mao, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052360 · Cited by 97
Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
Jutten, R. J., Sikkes, S. A. M., Van der Flier, W. M., Scheltens, P., Visser, P. J., Tijms, B. M., & Initiative, F. T. A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012022 · Cited by 81
“9,10,12,14,15 We further studied the in fl uence of known factors a ff ecting AD progression (i.e., age, sex, 18 educational level, 19 APOE e 4 status, 20 CSF tau levels 4 ) on the variability in e ff ect sizes.”
Jutten, R. J., Papp, K. V., Hendrix, S. B., Ellison, N., Langbaum, J. B. S., Donohue, M., Hassenstab, J. J., Maruff, P. T., Rentz, D. M., Harrison, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12773 · Cited by 88
“13,14 17 Despite these updates, however, most of the recent large Phase 3 AD clinical trials for prodromal to mild AD (e.g., in references 18–22 ) have incorporated the ADAS-Cog and the MMSE as primary or secondary endpoints.”
BackgroundLoeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
“A subsequent phase III trial with Solanezumab which was limited to patients with mild AD with evidence of cerebral A deposition (based on PET scan or CSF A 1-42 measurement) did not meet its primary end point, which was the change from baseline to week 80 in ADAS-Cog14 [226, 227].”
BackgroundAvgerinos, K. I., Manolopoulos, A., Ferrucci, L., & Kapogiannis, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-75204-8 · Cited by 95
“Overall, nine studies were at low risk of bias 4,6,22,24,25,30 , one at high risk 27 , and seven were deemed as having some concerns 5,23,26–28 .”
δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities
Zhang, Z., Tian, Y., & Ye, K. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-019-0179-3 · Cited by 77
“Unfortunately, they have thus far failed to produce effects that are clinically significant [32] [33] [34] [35] .”
BackgroundTosun, D., Veitch, D., Aisen, P., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Bollinger, J., Ovod, V., Mawuenyega, K. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab008 · Cited by 79
“A42 levels as a critical step in clinical trial cohort enrichment (Sperling et al., 2014; Honig et al., 2018).”
BackgroundAnti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Niki, K., Yahara, M., Inagaki, M., Takahashi, N., Watanabe, A., Okuda, T., Ueda, M., Iwai, D., Sato, K., & Ito, T. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.598161 · Cited by 80
“More recently, a series of phase 3 trials of new dementia drug candidates (Salloway et al., 2014; Honig et al., 2018; Wessels et al., 2019) ended in failure, highlighting the limitations of drug therapy for dementia.”
BackgroundJeremic, D., Navarro-López, J. D., & Jiménez-Díaz, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102012 · Cited by 77
In vitro models of molecular and nano-particle transport across the blood-brain barrier
Hajal, C., Campisi, M., Mattu, C., Chiono, V., & Kamm, R. D. (2018) · Biomicrofluidics · doi:10.1063/1.5027118 · Cited by 77
Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors
Michaels, T. C. T., Šarić, A., Meisl, G., Heller, G. T., Curk, S., Arosio, P., Linse, S. S., Dobson, C. M., Vendruscolo, M., & Knowles, T. P. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006684117 · Cited by 78
Hole, K. L., & Williams, R. J. (2020) · Brain Plasticity · doi:10.3233/bpl-200098 · Cited by 82
“Moreover, methods to reduce soluble and/or aggregated forms of A via antibody strategies have had disappointing outcomes [14, 15], although, it should be noted that recent reports claim that the A -targeting antibody Aducanumab meets its primary endpoint.”
MethodSharma, B., Satija, G., Madan, A., Garg, M., Alam, M. M., Shaquiquzzaman, M., Khanna, S., Tiwari, P., Parvez, S., Iqubal, A., et al. (2023) · Inflammation · doi:10.1007/s10753-022-01730-0 · Cited by 75
“It has been rising significantly over the years among the elderly population over the years [1].”
BackgroundProcyanidins and Alzheimer’s Disease
Zhao, S., Zhang, L., Yang, C., Li, Z., & Rong, S. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1469-6 · Cited by 80
Complement System in Alzheimer’s Disease
Shah, A., Kishore, U., & Shastri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413647 · Cited by 73
The potential of polygenic scores to improve cost and efficiency of clinical trials
Fahed, A. C., Philippakis, A., & Khera, A. V. (2022) · Nature Communications · doi:10.1038/s41467-022-30675-z · Cited by 82
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Tian, J., Guo, L., Sui, S., Driskill, C., Phensy, A., Wang, Q., Gauba, E., Zigman, J. M., Swerdlow, R. H., Kroener, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6278 · Cited by 72
Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
Husna Ibrahim, N., Yahaya, M. F., Mohamed, W., Teoh, S. L., Hui, C. K., & Kumar, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00261 · Cited by 72
“Solanezumab IgG1 humanized antiAb mAbs III Mild-tomoderate AD Lack of efficacy (Honig et al., 2018) Bapineurumab IgG1 humanized antiAb mAbs III Mild-tomoderate AD Lack of efficacy (Salloway et al., 2018) (Ketter et al., 2017) Crenezumab IgG1 humanized antiAb mAbs II Mild-tomoderate AD Lack of…”
BackgroundFecal Fungal Dysbiosis in Chinese Patients With Alzheimer’s Disease
Ling, Z., Zhu, M., Liu, X., Shao, L., Cheng, Y., Yan, X., Jiang, R., & Wu, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.631460 · Cited by 83
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 78
Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 85
Kenny, A., McArdle, H., Calero, M., Rabano, A., Madden, S. F., Adamson, K., Forster, R., Spain, E., Prehn, J. H. M., Henshall, D. C., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3429882 · Cited by 71
“The advanced stages of AD, at which clinical trials are applied, are often cited as a major contributor to the serial failures of AD therapeutic trials [3,4].”
BackgroundChen, L., Soldan, A., Oishi, K., Faria, A. V., Zhu, Y., Albert, M., van Zijl, P. C. M., & Li, X. (2020) · Radiology · doi:10.1148/radiol.2020201603 · Cited by 79
“However, large variability in the rate of cognitive decline among individuals with amyloid pathology (3,4) and ineffectiveness of antiamyloid therapeutics to slow cognitive decline (5,6) suggest that other factors, such as brain iron (7), may alter risk of cognitive decline (8,9).”
BackgroundKrashia, P., Nobili, A., & D'Amelio, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00123 · Cited by 71
Li, H., Ip, S., Yuan, Q., Zheng, G., Tsim, K. W. K., Dong, T. T.-X., Lin, G., Han, Y., Liu, Y., Xian, Y., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.08.194 · Cited by 72
Qiao, Y., Chi, Y., Zhang, Q., & Ma, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1169499 · Cited by 90
“In addition, the progress of drug development is not satisfactory because the research mainly aimed at binding Aβ monomer (solanezumab and crenezumab) or the mixture of monomer and plaques (bapineuzumab) failed to show clinical efficacy (Cummings et al., 2018; Honig et al., 2018; Long and Holtzman, 2019).”
BackgroundInsights into Computational Drug Repurposing for Neurodegenerative Disease
Paranjpe, M. D., Taubes, A., & Sirota, M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.003 · Cited by 70
“This need is highlighted by the consistent devastating failures of all clinical trials that have targeted canonical AD targets such as amyloid-beta[109]–[113].”
BackgroundAlzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 74
“Development of solanezumab has been halted in symptomatic patients due to its failure to reduce decline in cognition or function in 3 phase III trials (EXPEDITION 1–3) [55, 56].”
BackgroundGenome-wide association identifies the first risk loci for psychosis in Alzheimer disease
DeMichele-Sweet, M. A. A., Klei, L., Creese, B., Harwood, J. C., Weamer, E. A., McClain, L., Sims, R., Hernandez, I., Moreno-Grau, S., Tárraga, L., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01152-8 · Cited by 64
“Diagnoses were made based on diagnostic evaluations, cognitive testing, and in some cases neuropathologic assessment, conducted during subjects’ participation in the following eight source programs as previously described: the Fundació ACE Barcelona Alzheimer Treatment and Research Center (ACE/GR@ACE) [31–33], a Conso…”
MethodInfluentialSelf-citationQuantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Lopes Alves, I., Collij, L. E., Altomare, D., Frisoni, G. B., Saint‐Aubert, L., Payoux, P., Kivipelto, M., Jessen, F., Drzezga, A., Leeuwis, A., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12069 · Cited by 67
The Brain–Gut Axis, an Important Player in Alzheimer and Parkinson Disease: A Narrative Review
Caradonna, E., Nemni, R., Bifone, A., Gandolfo, P., Costantino, L., Giordano, L., Mormone, E., Macula, A., Cuomo, M., Difruscolo, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144130 · Cited by 83
“However, treatment with solanezumab (an Ab-targeted antibody) in patients with AD has failed to improve cognitive decline [31].”
BackgroundCurrent and evolving treatment strategies for the Alzheimer disease continuum
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 66
Zhang, H., Jiang, W., Zhao, Y., Song, T., Xi, Y., Han, G., Jin, Y., Song, M., Bai, K., Zhou, J., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00191 · Cited by 65
Imbimbo, B. P., Ippati, S., Watling, M., & Imbimbo, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106631 · Cited by 65
Raikwar, S. P., Thangavel, R., Dubova, I., Selvakumar, G. P., Ahmed, M. E., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1068-y · Cited by 73
Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system
Quitterer, U., & AbdAlla, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.014 · Cited by 77
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.